A Phase 2 interventional study of Fulvestrant and Anastrazole in Breast Cancer, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to female participants. Per ClinicalTrials.gov, last updated 2012-08-16.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 39th largest by enrollment of the 94 interventional ones that give a count, is one of 10 that started in 2004, is one of 59 in phase 2, and was the 17th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 10 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 72nd largest by enrollment of the 125 interventional ones that give a count, is one of 14 that started in 2004, is one of 31 in phase 2, and was the 18th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with primary breast cancer who are awaiting curative-intent surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anastrozole Monotherapy
Drug: Anastrazole
Fulvestrant Monotherapy
Drug: Fulvestrant
Anastrozole + Fulvestrant
Drug: Fulvestrant · Drug: Anastrazole
500 mg intramuscular injection
Also known as: Faslodex, ZD9238
oral tablet
Also known as: Arimidex, ZD1033
Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score.
For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)\]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score.
For each sample, the PgR H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent+/-) + (1 x percent+) + (2 x percent++) + (3 x percent+++)\]. Range 0-300. The greater the change from baseline (randomization in PgR H-score, the greater the blockage of PgR expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Percentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index.
For each sample, the Ki67 labelling index is calculated as the percentage of cells stained positive for Ki67. Range 0-100. The greater the change from baseline (randomization) in Ki67 labelling index, the greater the blockage of Ki67 expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
Time frame: Surgery (SRG) was to be performed between days 15 and 22 after baseline (BL)
Postmenopausal women with oestrogen receptor positive breast cancer, awaiting curative-intent surgery were recruited to 4 medical centres within the UK.
| Milestone | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| Started | 35 | 31 | 37 |
| Completed | 35 | 31 | 37 |
| Not completed | 0 | 0 | 0 |
For each sample, the ER H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)\]. Range 0-300. The greater the change from baseline (randomization) in ER H-score, the greater the blockage of ER expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
| Percentage change from baseline | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| Percentage Change From Baseline to Time of Surgery in Oestrogen Receptor (ER) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the ER H-score. | -37 ± 4 | -38 ± 5 | -7 ± 6 |
For each sample, the PgR H-score is calculated from the percentage of cells staining very weak (+/-); weak (+); moderate (++); or strong (+++) as follows: H-score = \[(0.5 x percent+/-) + (1 x percent+) + (2 x percent++) + (3 x percent+++)\]. Range 0-300. The greater the change from baseline (randomization in PgR H-score, the greater the blockage of PgR expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
| Percentage change from baseline | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| Percentage Change From Baseline to Time of Surgery in Progesterone Receptor (PgR) H-score: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the PgR H-score. | -31 ± 8 | -38 ± 12 | -38 ± 7 |
For each sample, the Ki67 labelling index is calculated as the percentage of cells stained positive for Ki67. Range 0-100. The greater the change from baseline (randomization) in Ki67 labelling index, the greater the blockage of Ki67 expression and the greater the potential anti-tumour activity. Percentage change from baseline=\[(SRG - BL)/BL\]x100
| Percentage change from baseline | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| Percentage Change From Baseline to Time of Surgery in Ki67 Labelling Index: Antitumour Effects of Fulvestrant, Anastrozole and a Combination of Both as Measured by the Ki67 Labelling Index. | -62 ± 4 | -68 ± 6 | -75 ± 4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant | — | 0/40 (0%) | 18/40 (45%) |
| Fulvestrant + Anastrozole | — | 3/40 (7.5%) | 13/40 (32.5%) |
| Anastrozole | — | 2/40 (5%) | 17/40 (42.5%) |
| Event | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| PancytopeniaBlood and lymphatic system disorders | 0/40 | 0/40 | 1/40 |
| Atrial FibrillationCardiac disorders | 0/40 | 1/40 | 0/40 |
| Unevaluable EventGeneral disorders | 0/40 | 1/40 | 0/40 |
| Subcutaneous AbscessInfections and infestations | 0/40 | 0/40 | 1/40 |
| Procedural ComplicationInjury, poisoning and procedural complications | 0/40 | 1/40 | 0/40 |
| Event | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole |
|---|---|---|---|
| Hot FlushVascular disorders | 7/40 | 3/40 | 8/40 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 0/40 | 4/40 | 2/40 |
| HeadacheNervous system disorders | 3/40 | 4/40 | 3/40 |
| ConstipationGastrointestinal disorders | 3/40 | 1/40 | 2/40 |
| DyspepsiaGastrointestinal disorders | 3/40 | 0/40 | 1/40 |
| NauseaGastrointestinal disorders | 0/40 | 3/40 | 2/40 |
| Injection Site RashGeneral disorders | 3/40 | 0/40 | 0/40 |
| Unevaluable EventGeneral disorders | 3/40 | 0/40 | 3/40 |
| Injection Site PainGeneral disorders | 2/40 | 1/40 | 3/40 |
| RashSkin and subcutaneous tissue disorders | 1/40 | 3/40 | 0/40 |
| Age, Customized(Participants) | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|---|
| 50 - 59 years | 7 ± 8.5 | 13 ± 10.5 | 10 ± 8.7 | 30 ± 9.0 |
| 60 - 69 years | 13 | 7 | 14 | 34 |
| 70 - 79 years | 13 | 6 | 9 | 28 |
| 80 - 89 years | 2 | 3 | 2 | 7 |
| Not available | 0 | 2 | 2 | 4 |
| Sex: Female, Male(Participants) | Fulvestrant | Fulvestrant + Anastrozole | Anastrozole | Total |
|---|---|---|---|---|
| Female | 35 | 31 | 37 | 103 |
| Male | 0 | 0 | 0 | 0 |
The record gives a start of Apr 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fulvestrant · Anastrozole